Spermosens

The decision to move to a more space-efficient office reflects Spermosens' strategic focus on advancing its clinical study and ongoing discussions with potential partners. By optimizing resources, the Company ensures that its efforts remain directed toward achieving key milestones and creating long-term value for shareholders.

Tore Duvold, CEO of Spermosens, comments: "The relocation aligns with our cost-conscious approach and strategic priorities. By streamlining our operations, we can dedicate most of our resources to our clinical study and partner discussions, which are critical for demonstrating the value of our JUNO-Checked technology and advancing commercialization efforts."

Spermosens remains fully operational at Medicon Village, The Spark, a leading hub for life science innovation, providing access to collaboration opportunities and resources to support the Company's growth and development.

For more information, please contact 

Tore Duvold, CEO

info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com